Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results
Date:2/28/2012

we generated $170.7 million in cash flow from operations and deployed $170.0 million to repurchase 9.2 million shares during 2011.

Looking ahead in 2012ViroPharma is reiterating its guidance for the year 2012 as a convenience to investors.  The following guidance provided by ViroPharma are projections, based upon numerous assumptions, all of which are subject to certain risks and uncertainties.  For a discussion of the risks and uncertainties associated with these forward looking statements, please see the Disclosure Notice below.

For the year 2012, ViroPharma expects the following:

  • Worldwide net product sales are expected to be $600 to $660 million;
  • Net U.S. Cinryze sales are expected to be $310 to $330 million;
  • Net Vancocin sales are expected to be $260 to $310 million; and
  • Research and development (R&D) and selling, general and administrative (SG&A) expenses are expected to be $230 to $260 million.

  • Non-GAAP DisclosuresThe Company is reporting both GAAP net income  and non-GAAP adjusted results for the three and twelve months ended December 31, 2011 and 2010.   Non-GAAP adjusted net income is GAAP net income excluding (1) non-cash interest expense, (2) amortization related intangible assets acquired, (3) stock compensation expenses, and (4) certain non-recurring events. Non-GAAP adjusted diluted net income per share reflects the Non-GAAP adjusted net income, after the incremental effect of applying the "if converted" method of accounting to the senior convertible notes, and the diluted shares used in determining our GAAP diluted net income per share. A reconciliation between GAAP and non-GAAP adjusted measures is provided in the Selected Financial Information – Non-GAAP Financial Measures Reconciliation table included with this release. The Company believes that its presentation of historical non-GAAP financial measure
    '/>"/>

    SOURCE ViroPharma Incorporated
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related biology technology :

    1. ViroPharma to Present at Three September Healthcare Conferences
    2. ViroPharma to Present at Three October Healthcare Conferences
    3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
    4. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
    5. ViroPharma to Present at Three November Healthcare Conferences
    6. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
    7. ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
    8. ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
    9. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
    10. ViroPharma Incorporated Honored by the National Organization for Rare Disorders
    11. ViroPharma to Present at Two June Healthcare Conferences
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/26/2014)... The Pittcon marketing department is pleased to announce ... app, Pittcon 2015 . The ... for iOS and Android devices and the Kindle Fire, ... after the event. It acts as an all-inclusive real-time ... Conferee Networking sessions and short courses. , The Pittcon ...
    (Date:11/26/2014)... WILMINGTON, DE (PRWEB) November 26, 2014 ... MPN Heroes recognition reception on December 5, 2014, in ... annual meeting. The MPN Heroes event will honor clinicians, ... the field of myeloproliferative neoplasms (MPNs). , Special ... will discuss his family's cancer journey at the reception. ...
    (Date:11/26/2014)... 2014 /PRNewswrie/ -- Theravalues Corporation annuncia con orgoglio il ... occasione di Hi Europe 2014 (dal 2 al 4 ... tratta della curcumina con la maggiore biodisponibilità di sempre, ... ingredienti approvati dalle norme europee. La curcumina ... curcumina ( Curcuma longa ) che è stata associata ...
    (Date:11/24/2014)... WASHINGTON , Nov. 24, 2014  Last ... G.K. Butterfield (D-NC) took a bold ... diseases by introducing the OPEN Act. Original co-sponsors ... Hastings (D-FL). The Act will incentivize drug makers ... life-threatening rare diseases and pediatric cancers, which opens ...
    Breaking Biology Technology:Pittcon Releases 2015 Mobile App 2CURE Magazine and Incyte to Honor MPN Heroes 2CURE Magazine and Incyte to Honor MPN Heroes 3CURE Magazine and Incyte to Honor MPN Heroes 4La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2
    ... (Wednesday, Sept. 1, 2010) - A new "smart ... developed by University of Waterloo engineering researchers promises ... as medical devices, microelectromechanical systems (MEMS), printers, hard ... The breakthrough technology will provide engineers with much ...
    ... 1 TriMark Publications, LLC ( http://www.trimarkpublications.com ), a ... publishing, cites in its newly published Regenerative Medicine ... medicine products will exceed $3 billion in 2010 and ... medicine is a technique to treat injuries and diseases ...
    ... 1, 2010 ... ... var shortURL = ... so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; ...
    Cached Biology Technology:New process promises to revolutionize manufacturing of products 2Regenerative Medicine Market Expected to Reach $4.5 Billion by 2014 2ReproCELL Announces New Line of Services in Neuronal Research Using Human iPS Cells 2ReproCELL Announces New Line of Services in Neuronal Research Using Human iPS Cells 3ReproCELL Announces New Line of Services in Neuronal Research Using Human iPS Cells 4ReproCELL Announces New Line of Services in Neuronal Research Using Human iPS Cells 5ReproCELL Announces New Line of Services in Neuronal Research Using Human iPS Cells 6
    (Date:11/11/2014)... 2014  Forensicon, Inc., a Chicago ... announce the promotion of Yaniv Schiff from ... In Schiff,s new role as Director, he will lead ... forensics examiners and provide leadership within the company,s digital ... http://photos.prnewswire.com/prnh/20141110/157719 Schiff joined Forensicon in ...
    (Date:11/6/2014)... a team of Florida State University biologists could lead ... to and survive environmental swings such as droughts or ... of the journal The Plant Cell , sheds ... proteins) is organized in a cell and how plants ... on and others are turned off. , "If you ...
    (Date:11/5/2014)... – Kelly Redmond has dedicated his career to ... to a general audience. , As deputy director ... Center at Nevada,s Desert Research Institute, Redmond has ... management, application and dissemination of climate data to ... Fall Meeting in San Francisco on December 15-19, ...
    Breaking Biology News(10 mins):Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2Maize analysis yields whole new world of genetic science 2Nevada climatologist to be honored at AGU Fall Meeting for lifetime of public outreach 2
    ... a researcher from the Tropical Research Institute of Portugal had ... a staple food crop for half of humanity ... shunned by consumers worldwide. She realised she could not do ... collaboration to address a looming threat to world,s rice supplies. ...
    ... March 17, 2010 -- University of Miami (UM) Rosenstiel School ... developed a new tool to monitor coral reef vital signs. ... how climate change and other ecological threats impact coral reef ... a March 2009 experiment at Cayo Enrique Reef in Puerto ...
    ... A dendritic cell vaccine personalized for each individual based on ... those with a deadly form of brain cancer called glioblastoma, ... has found. Published this week ... study also identified a subset of patients more likely to ...
    Cached Biology News:Chemical-free pest management cuts rice waste 2Chemical-free pest management cuts rice waste 3Study provides new tool to monitor coral reef 'vital signs' 2Personlized dendritic cell vaccine increases survival in patients with deadly brain cancer 2Personlized dendritic cell vaccine increases survival in patients with deadly brain cancer 3
    The BioLogic Maximizer mixer is for use with the Maximizer valve system. The mixer improves gradient quality by mixing the output of the BioLogic DuoFlow workstation pumps....
    PTC-100 cycler with gold/silver block with Hot Bonnet heated lid, holds one 96-well V-plate or96x0.2ml tubes...
    ... maximum performance on minimum space. Thanks to ... heating and cooling rates have been achieved ... a maximum capacity of 48 x 0.2ml ... of much more expensive 96 well instruments. ...
    ... Super Sensitive Polymer-HRP IHC ... novel product based on ... technology. This system yields ... noise ratio and minimizes ...
    Biology Products: